Anlotinib Plus Platinum-etoposide As a First-line Treatment for Extensive-stage Small Cell Lung Cancer: A Single-arm Trial

Overview

Journal Cancer Med

Specialty Oncology

Date 2022 May 8

PMID 35526266

Authors

Pengbo Deng

Chengping Hu

Cen Chen

Liming Cao

Qihua Gu

Jian An

Ling Qin

Min Li

Baimei He

Juan Jiang

Huaping Yang

Affiliations

Soon will be listed here.

Abstract

Background: Anlotinib as a third-line or beyond therapy for extensive-stage small-cell lung cancer (ES-SCLC) was studied. This single-arm phase II trial was to investigate the value of anlotinib plus platinum-etoposide as first-line treatment in ES SCLC.

Methods: The primary endpoint was progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included overall survival (OS), disease control rate (DCR), time to progression (TTP), duration of remission (DoR), and safety. The subgroups of preset liver metastasis and brain metastasis were analyzed.

Results: In 35 ES-SCLC patients, the median PFS, ORR, DCR, and OS were 8.02 months [95% confidence interval (CI): 6.90-9.66], 85.71% (95% CI: 69.74-95.19), 94.29% (95% CI: 80.84-99.30), and 15.87 months (95% CI: 10.38-18.89), respectively. The median PFS in the liver metastasis and brain metastasis subgroups was 7.33 months (95% CI: 4.76-9.69) and 7.34 months (95% CI: 5.68-9.20), respectively. The most common AEs with grade 3-4 were hand-foot syndrome (17%), granulocytosis (17%), stomatitis (14%), hypertriglyceridemia (11%), hypercholesterolemia (11%), as well as nausea and vomiting (11%), and no grade 5 AEs were recorded.

Conclusions: Anlotinib combined with platinum-etoposide provided an effective and safe therapy for patients with ES-SCLC.

Citing Articles

Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review.

Wang J, Li X, Dong S, Hu S, Ran F, Qian Y Front Oncol. 2025; 15:1525881.

PMID: 39995840 PMC: 11847684. DOI: 10.3389/fonc.2025.1525881.

Efficacy and safety of anlotinib as maintenance treatment in extensive-stage small cell lung cancer: a single-armed single center retrospective study.

Xiong J, Xia L Front Oncol. 2025; 14:1462581.

PMID: 39876899 PMC: 11772156. DOI: 10.3389/fonc.2024.1462581.

Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies.

Jang J, Kim D, Im E, Kim N Int J Mol Sci. 2025; 26(2).

PMID: 39859509 PMC: 11765581. DOI: 10.3390/ijms26020796.

The Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Anlotinib and PD-1/L1 Inhibitors For Treating Patients With Extensive-Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study.

Li X, Wu D, Peng Y, Tang J, Wu Y Cancer Med. 2024; 13(23):e70449.

PMID: 39660471 PMC: 11632393. DOI: 10.1002/cam4.70449.

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study.

Lv X, Liu Y, Feng Y, Liang H, Zhi W J Cancer. 2024; 15(11):3539-3546.

PMID: 38817880 PMC: 11134448. DOI: 10.7150/jca.91701.

References

Landre T, Chouahnia K, Des Guetz G, Duchemann B, Assie J, Chouaid C . First-line immune-checkpoint inhibitor plus chemotherapy chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Ther Adv Med Oncol. 2020; 12:1758835920977137. PMC: 7731693. DOI: 10.1177/1758835920977137. View

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z . Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018; 4(11):1569-1575. PMC: 6248083. DOI: 10.1001/jamaoncol.2018.3039. View

Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos D . Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012; 30(14):1692-8. DOI: 10.1200/JCO.2011.40.4905. View

Deng P, Hu C, Chen C, Cao L, Gu Q, An J . Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial. Cancer Med. 2022; 11(19):3563-3571. PMC: 9554443. DOI: 10.1002/cam4.4736. View

Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S . Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol. 2017; 35(12):1281-1287. DOI: 10.1200/JCO.2016.69.4844. View

Lara Jr P, Natale R, Crowley J, Lenz H, Redman M, Carleton J . Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009; 27(15):2530-5. PMC: 2684855. DOI: 10.1200/JCO.2008.20.1061. View

Giaccone G, Ferrati P, Donadio M, Testore F, CALCIATI A . Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987; 23(11):1697-9. DOI: 10.1016/0277-5379(87)90452-4. View

Oronsky B, Reid T, Oronsky A, Carter C . What's New in SCLC? A Review. Neoplasia. 2017; 19(10):842-847. PMC: 5596356. DOI: 10.1016/j.neo.2017.07.007. View

Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L . Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer. 2021; 125(3):366-371. PMC: 8329046. DOI: 10.1038/s41416-021-01356-3. View

10.

Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z . Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018; 11(1):120. PMC: 6146601. DOI: 10.1186/s13045-018-0664-7. View

11.

Wang J, Zhao Y, Wang Q, Zhang L, Shi J, Wang Z . Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. Cancer Biol Med. 2019; 15(4):443-451. PMC: 6372914. DOI: 10.20892/j.issn.2095-3941.2018.0158. View

12.

Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T . Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007; 97(2):162-9. PMC: 2360311. DOI: 10.1038/sj.bjc.6603810. View

13.

Lu H, Fang L, Wang X, Cai J, Mao W . A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Mol Clin Oncol. 2014; 2(5):805-810. PMC: 4106745. DOI: 10.3892/mco.2014.311. View

14.

Higgins M, Ettinger D . Chemotherapy for lung cancer: the state of the art in 2009. Expert Rev Anticancer Ther. 2009; 9(10):1365-78. DOI: 10.1586/era.09.115. View

15.

Postmus P, Berendsen H, van Zandwijk N, Splinter T, Burghouts J, Bakker W . Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987; 23(9):1409-11. DOI: 10.1016/0277-5379(87)90128-3. View

16.

Yang S, Zhang Z, Wang Q . Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019; 12(1):47. PMC: 6498593. DOI: 10.1186/s13045-019-0736-3. View

17.

Zhu Y, Zhang H, Liu Y, Bai J, Li Y, Liu L . Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer. Oncol Lett. 2017; 14(1):655-664. PMC: 5494762. DOI: 10.3892/ol.2017.6249. View

18.

Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S . Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol. 2015; 21(41):11621-35. PMC: 4631965. DOI: 10.3748/wjg.v21.i41.11621. View

19.

Kahnert K, Kauffmann-Guerrero D, Maria Huber R . SCLC-State of the Art and What Does the Future Have in Store?. Clin Lung Cancer. 2016; 17(5):325-333. DOI: 10.1016/j.cllc.2016.05.014. View

20.

Hoffman P, Mauer A, Vokes E . Lung cancer. Lancet. 2000; 355(9202):479-85. DOI: 10.1016/S0140-6736(00)82038-3. View